Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Humatrope in adults with growth hormone deficiency
NCT00191360Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2003
- Modality
- Hormone, rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of somatropin in growth hormone deficiency (GHD), sponsored by Eli Lilly and Company. Primary endpoint: Long-term safety of growth hormone replacement. Started Jan 2003; status: completed.
02
Drugs
somatropin
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on NCT00191360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00191360.